Page last updated: 2024-12-06

befloxatone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Befloxatone is a selective inhibitor of the enzyme monoamine oxidase type A (MAO-A). It was initially developed as an antidepressant but was withdrawn from the market due to concerns about potential hepatotoxicity. Despite its withdrawal, befloxatone remains an interesting compound for research due to its unique pharmacological profile. Its selective MAO-A inhibition offers potential for treating depression, anxiety, and other conditions related to monoamine neurotransmitter dysfunction. However, its potential for liver toxicity limits its clinical application. Researchers continue to study befloxatone, focusing on its potential benefits for treating neurodegenerative diseases, such as Parkinson's disease, and its potential for developing safer and more effective MAO-A inhibitors.'

befloxatone: selectively inhibits monoamine oxidase A; structure in first source; RN given refers to (R)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID60824
CHEMBL ID416578
SCHEMBL ID464941
MeSH IDM0237906

Synonyms (28)

Synonym
md370503
md 370503
md-370,503
md-370503
D02563
befloxatone (inn)
134564-82-2
befloxatone
CHEMBL416578
(5r)-5-(methoxymethyl)-3-[4-[(3r)-4,4,4-trifluoro-3-hydroxybutoxy]phenyl]-1,3-oxazolidin-2-one
bdbm50361617
4h75pad8m3 ,
2-oxazolidinone, 5-(methoxymethyl)-3-(4-(4,4,4-trifluoro-3-hydroxybutoxy)phenyl)-, (r,(r*,r*))-
unii-4h75pad8m3
befloxatone [inn]
(r)-5-(methoxymethyl)-3-(p-((r)-4,4,4-trifluoro-3-hydroxybutoxy)phenyl)-2-oxazolidinone
befloxatone [mi]
befloxatone [who-dd]
befloxatone [mart.]
gtpl6637
SCHEMBL464941
DTXSID70158800
Q4880243
2-acetamido-3,4,6-tri-o-acetyl-2-deoxy-beta-d-glucopyranosylisothiocyanate
CS-0068863
HY-120017
ialvdlplclfbcf-chwsqxevsa-n
AKOS040747934

Research Excerpts

Overview

Befloxatone is a competitive and reversible inhibitor of monoamine oxidase-A (MAOI-A) It has been shown to have antidepressant activity in various animal models.

ExcerptReferenceRelevance
"[C]Befloxatone is a highly specific, reversible, and selective radioligand for brain PET imaging of monoamine oxidase-A and can be quantified by a two-tissue compartment model (2TCM) and an arterial input function. "( Imaging of monoamine oxidase-A in the human brain with [11C]befloxatone: quantification strategies and correlation with mRNA transcription maps.
Bottlaender, M; Leroy, C; Martinot, JL; Rizzo, G; Roumenov, D; Trichard, C; Zanotti-Fregonara, P, 2014
)
1.27
"Befloxatone is a competitive and reversible inhibitor of monoamine oxidase-A (MAOI-A). "( Mapping the cerebral monoamine oxidase type A: positron emission tomography characterization of the reversible selective inhibitor [11C]befloxatone.
Bottlaender, M; Bramoulle, Y; Curet, O; Dolle, F; Fuseau, C; George, P; Guenther, I; Jegham, J; Pinquier, JL; Roumenov, D; Valette, H, 2003
)
1.96
"Befloxatone is a new reversible and selective monoamine oxidase (MAO-A) inhibitor that has been shown to have antidepressant activity in various animal models. "( Effects of befloxatone, a reversible selective monoamine oxidase-A inhibitor, on psychomotor function and memory in healthy subjects.
Berlin, I; Durrieu, G; Patat, A; Puech, AJ; Warot, D; Zieleniuk, I, 1996
)
2.13
"Befloxatone is a new antidepressant with a potent, selective, competitive, and reversible inhibitory activity on the A isoform of monoamine oxidase (MAO-A)."( Cognitive performance in elderly subjects after a single dose of befloxatone, a new reversible selective monoamine oxidase A inhibitor.
Allain, H; Cimarosti, I; Gandon, JM; Patat, A; Rosenzweig, P; Zieleniuk, I, 1998
)
1.26

Pharmacokinetics

ExcerptReferenceRelevance
"The pharmacodynamic equipotency of 2 dose regimens (5 mg twice daily versus 10 mg once daily) of befloxatone, a new reversible and selective monoamine oxidase A (MAO-A) inhibitor, after single and multiple doses for 6 days was examined in a randomized, double-blind, three-way crossover, placebo-controlled trial of 12 healthy volunteers."( Pharmacodynamics and pharmacokinetics of two dose regimens of befloxatone, a new reversible and selective monoamine oxidase inhibitor, at steady state in healthy volunteers.
Allain, H; Cimarosti, I; Curet, O; Dubruc, C; Durrieu, G; Gandon, JM; Jezequel, S; le Coz, F; Patat, A; Rosenzweig, P; Zieleniuk, I, 1996
)
0.75

Bioavailability

ExcerptReferenceRelevance
" The pharmacokinetic bioavailability at steady state of both dose regimens was also similar."( Pharmacodynamics and pharmacokinetics of two dose regimens of befloxatone, a new reversible and selective monoamine oxidase inhibitor, at steady state in healthy volunteers.
Allain, H; Cimarosti, I; Curet, O; Dubruc, C; Durrieu, G; Gandon, JM; Jezequel, S; le Coz, F; Patat, A; Rosenzweig, P; Zieleniuk, I, 1996
)
0.53

Dosage Studied

ExcerptRelevanceReference
" These results are similar to those reported with the therapeutic dosage of other selective MAO-A inhibitors."( Pressor effect of oral tyramine during treatment with befloxatone, a new reversible monoamine oxidase-A inhibitor, in healthy subjects.
Armand, P; Berlin, I; Caille, P; Durrieu, G; Fitoussi, S; Molinier, P; Patat, A, 1995
)
0.54
" Both dose regimens provided equipotent extent and duration of MAO-A inhibition at steady state, suggesting a once daily dosage should be sufficient for most patients."( Pharmacodynamics and pharmacokinetics of two dose regimens of befloxatone, a new reversible and selective monoamine oxidase inhibitor, at steady state in healthy volunteers.
Allain, H; Cimarosti, I; Curet, O; Dubruc, C; Durrieu, G; Gandon, JM; Jezequel, S; le Coz, F; Patat, A; Rosenzweig, P; Zieleniuk, I, 1996
)
0.53
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Amine oxidase [flavin-containing] A Bos taurus (cattle)Ki0.00250.00251.35733.8000AID641691
Amine oxidase [flavin-containing] BBos taurus (cattle)Ki0.22000.05401.83906.0000AID641692
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Amine oxidase [flavin-containing] AHomo sapiens (human)KiA0.00350.00350.00350.0035AID126360
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (4)

Processvia Protein(s)Taxonomy
biogenic amine metabolic processAmine oxidase [flavin-containing] AHomo sapiens (human)
positive regulation of signal transductionAmine oxidase [flavin-containing] AHomo sapiens (human)
dopamine catabolic processAmine oxidase [flavin-containing] AHomo sapiens (human)
catecholamine metabolic processAmine oxidase [flavin-containing] A Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (5)

Processvia Protein(s)Taxonomy
protein bindingAmine oxidase [flavin-containing] AHomo sapiens (human)
primary amine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
aliphatic amine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
monoamine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
flavin adenine dinucleotide bindingAmine oxidase [flavin-containing] AHomo sapiens (human)
primary amine oxidase activityAmine oxidase [flavin-containing] A Bos taurus (cattle)
aliphatic amine oxidase activityAmine oxidase [flavin-containing] A Bos taurus (cattle)
monoamine oxidase activityAmine oxidase [flavin-containing] A Bos taurus (cattle)
primary amine oxidase activityAmine oxidase [flavin-containing] BBos taurus (cattle)
aliphatic amine oxidase activityAmine oxidase [flavin-containing] BBos taurus (cattle)
monoamine oxidase activityAmine oxidase [flavin-containing] BBos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
mitochondrionAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrial outer membraneAmine oxidase [flavin-containing] AHomo sapiens (human)
cytosolAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrial outer membraneAmine oxidase [flavin-containing] A Bos taurus (cattle)
mitochondrionAmine oxidase [flavin-containing] BBos taurus (cattle)
mitochondrial outer membraneAmine oxidase [flavin-containing] BBos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (14)

Assay IDTitleYearJournalArticle
AID641693Selectivity index, ratio of Ki for bovine MAOB to Ki for bovine MAOA2011Journal of medicinal chemistry, Dec-08, Volume: 54, Issue:23
Novel reversible monoamine oxidase A inhibitors: highly potent and selective 3-(1H-pyrrol-3-yl)-2-oxazolidinones.
AID23985Logarithm of capacity factor was determined1998Bioorganic & medicinal chemistry letters, Jun-02, Volume: 8, Issue:11
Molecular lipophilicity potential by CLIP, a reliable tool for the description of the 3D distribution of lipophilicity: application to 3-phenyloxazolidin-2-one, a prototype series of reversible MAOA inhibitors.
AID126218Compound was tested for inhibition of MAOA in rat brain, heart, liver and duodenum homogenates; Range is 1.9-3.6 nM2003Bioorganic & medicinal chemistry letters, May-19, Volume: 13, Issue:10
Synthesis and in vivo imaging properties of [11C]befloxatone: a novel highly potent positron emission tomography ligand for mono-amine oxidase-A.
AID23224Partition coefficient (logP)1998Bioorganic & medicinal chemistry letters, Jun-02, Volume: 8, Issue:11
Molecular lipophilicity potential by CLIP, a reliable tool for the description of the 3D distribution of lipophilicity: application to 3-phenyloxazolidin-2-one, a prototype series of reversible MAOA inhibitors.
AID25403Half life was determined2003Bioorganic & medicinal chemistry letters, May-19, Volume: 13, Issue:10
Synthesis and in vivo imaging properties of [11C]befloxatone: a novel highly potent positron emission tomography ligand for mono-amine oxidase-A.
AID592683Apparent permeability from basolateral side to apical side of human Caco2 cells by LC/MS/MS analysis2011Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8
QSAR-based permeability model for drug-like compounds.
AID114060Oral effective dose against phenylethylamine-induced stereotypy in mice2003Bioorganic & medicinal chemistry letters, May-19, Volume: 13, Issue:10
Synthesis and in vivo imaging properties of [11C]befloxatone: a novel highly potent positron emission tomography ligand for mono-amine oxidase-A.
AID125690Compound was tested for inhibition of MAOA in human brain, heart, liver and duodenum homogenates; Range is 1.9-3.6 nM2003Bioorganic & medicinal chemistry letters, May-19, Volume: 13, Issue:10
Synthesis and in vivo imaging properties of [11C]befloxatone: a novel highly potent positron emission tomography ligand for mono-amine oxidase-A.
AID592682Apparent permeability from apical to basolateral side of human Caco2 cells after 2 hrs by LC/MS/MS analysis2011Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8
QSAR-based permeability model for drug-like compounds.
AID641692Inhibition of bovine brain MAOB using kynuramine as a substrate after 30 mins by spectrofluorometric method2011Journal of medicinal chemistry, Dec-08, Volume: 54, Issue:23
Novel reversible monoamine oxidase A inhibitors: highly potent and selective 3-(1H-pyrrol-3-yl)-2-oxazolidinones.
AID113876Intravenous effective dose against L-5-hydroxytryptophan induced generalized tremors in mice2003Bioorganic & medicinal chemistry letters, May-19, Volume: 13, Issue:10
Synthesis and in vivo imaging properties of [11C]befloxatone: a novel highly potent positron emission tomography ligand for mono-amine oxidase-A.
AID126360Monoamine oxidase A inhibitory potency1998Bioorganic & medicinal chemistry letters, Jun-02, Volume: 8, Issue:11
Molecular lipophilicity potential by CLIP, a reliable tool for the description of the 3D distribution of lipophilicity: application to 3-phenyloxazolidin-2-one, a prototype series of reversible MAOA inhibitors.
AID114059Oral effective dose against L-5-hydroxytryptophan induced generalized tremors in mice; Range is 0.1-0.2 mg/Kg2003Bioorganic & medicinal chemistry letters, May-19, Volume: 13, Issue:10
Synthesis and in vivo imaging properties of [11C]befloxatone: a novel highly potent positron emission tomography ligand for mono-amine oxidase-A.
AID641691Inhibition of bovine brain MAOA using kynuramine as a substrate after 30 mins by spectrofluorometric method2011Journal of medicinal chemistry, Dec-08, Volume: 54, Issue:23
Novel reversible monoamine oxidase A inhibitors: highly potent and selective 3-(1H-pyrrol-3-yl)-2-oxazolidinones.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (35)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's20 (57.14)18.2507
2000's7 (20.00)29.6817
2010's8 (22.86)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 23.96

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index23.96 (24.57)
Research Supply Index3.74 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index26.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (23.96)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials6 (17.14%)5.53%
Reviews1 (2.86%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other28 (80.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]